856 related articles for article (PubMed ID: 23625945)
1. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
5. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
[TBL] [Abstract][Full Text] [Related]
6. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).
Zannad F; McMurray JJ; Drexler H; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
Eur J Heart Fail; 2010 Jun; 12(6):617-22. PubMed ID: 20388647
[TBL] [Abstract][Full Text] [Related]
8. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
Krum H; Mohacsi P; Katus HA; Tendera M; Rouleau JL; Fowler MB; Coats AJ; Roecker EB; Packer M;
Am Heart J; 2006 Jan; 151(1):55-61. PubMed ID: 16368292
[TBL] [Abstract][Full Text] [Related]
9. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
Collier TJ; Pocock SJ; McMurray JJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
Eur Heart J; 2013 Sep; 34(36):2823-9. PubMed ID: 23864130
[TBL] [Abstract][Full Text] [Related]
10. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
[TBL] [Abstract][Full Text] [Related]
11. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
Pölzl G; Gouya G; Hügel H; Frick M; Ulmer H; Pachinger O
Wien Klin Wochenschr; 2002 Oct; 114(19-20):833-9. PubMed ID: 12503474
[TBL] [Abstract][Full Text] [Related]
12. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Preiss D; van Veldhuisen DJ; Sattar N; Krum H; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B; Zannad F; McMurray JJ
Eur J Heart Fail; 2012 Aug; 14(8):909-15. PubMed ID: 22611047
[TBL] [Abstract][Full Text] [Related]
13. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
[TBL] [Abstract][Full Text] [Related]
14. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
16. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
[TBL] [Abstract][Full Text] [Related]
17. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
Dimopoulos K; Salukhe TV; Coats AJ; Mayet J; Piepoli M; Francis DP
Int J Cardiol; 2004 Feb; 93(2-3):105-11. PubMed ID: 14975535
[TBL] [Abstract][Full Text] [Related]
18. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B;
Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868
[TBL] [Abstract][Full Text] [Related]
19. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
Heywood JT; Fonarow GC; Yancy CW; Albert NM; Curtis AB; Gheorghiade M; Inge PJ; McBride ML; Mehra MR; O'Connor CM; Reynolds D; Walsh MN
Circ Heart Fail; 2010 Sep; 3(5):596-605. PubMed ID: 20634483
[TBL] [Abstract][Full Text] [Related]
20. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations.
Rogers JK; McMurray JJ; Pocock SJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
Circulation; 2012 Nov; 126(19):2317-23. PubMed ID: 23042980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
